Chemo Experts, the easiest way to learn about cancer treatment
Find a Treatment:
Cancer Types

Treatment Name: Inotuzumab (Besponsa®)

Inotuzumab (Besponsa®) is an Immunotherapy Regimen for Acute Lymphoid Leukemia (ALL)

Thank you for visiting our Inotuzumab (Besponsa®) page.

  • If you are interested in seeing the full treatment regimen page for Inotuzumab (Besponsa®) sooner rather than later, please click here to cast your vote for this specific regimen.
  • Votes from users like you are important as they help us prioritize the order in which we build our content. The more requests we receive, the faster we will build it!

While we work on uploading the pages that matter to you most, we hope that links to journal article references for Inotuzumab (Besponsa®) shown below will prove useful in the meantime.

Thank you for your continued support!

The ChemoExperts Team


1) Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375:740-753.

Created: February 14, 2019 Updated: February 14, 2019

What is Acute Lymphoid Leukemia (ALL)?

Acute Lymphoid Leukemia (ALL), also known as acute lymphoblastic leukemia, is a disease of the lymphoid cells found in the bone marrow. Lymphoid cells are responsible for developing into cells of the immune system called B-cells, T-cells, or Natural Killer cells. In ALL, immature lymphoid cells know as "blasts" replicate at a very fast rate. Sometimes blasts crowd out the normal cells in the bone marrow so that red blood cells or platelets are unable to develop.

Common symptoms of ALL include fatigue, infection, and bruising or bleeding. ALL is the most common cancer diagnosed in children, but is rare in adults. Most cases of ALL are considered "de novo" meaning that the cause is unknown; however, some cases can be linked to certain genetic syndromes. There is no staging system for ALL. Chromosomes are often analyzed to determine which mutations in the chromosomes exist. The effectiveness of the treatment may depend upon the specific chromosome mutations that are present.

NOTE: Treatment Options listed below are not all-inclusive. Other treatments may be available. ChemoExperts provides drug information and does not recommend any one treatment over another. Only your Doctor can choose your therapy.

Common inotuzumab ozogamicin (Besponsa®) starting doses

  • Induction therapy: Inotuzumab ozogamicin 0.8 mg/m2 intravenous (I.V.) infusion over 60 minutes on Day 1, then 0.5 mg/m2 I.V. infusion over 60 minutes on Days 8 and 15
    • If in complete response: Inotuzumab ozogamicin 0.5 mg/m2 I.V. infusion over 60 minutes on Days 1, 8, and 15
    • If not in complete response: Inotuzumab ozogamicin 0.8 mg/m2 I.V. infusion over 60 minutes on Day 1, then 0.5 mg/m2 I.V. infusion over 60 minutes on Days 8 and 15